Phase II trial of IPH 2201 in combination with durvalumab (MEDI 4736) in patients with solid tumours

Trial Profile

Phase II trial of IPH 2201 in combination with durvalumab (MEDI 4736) in patients with solid tumours

Planning
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2015

At a glance

  • Drugs Durvalumab (Primary) ; Monalizumab (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 28 Apr 2015 New trial record
    • 24 Apr 2015 Innate Pharma and AstraZeneca, along with MedImmune, have signed a co-development agreement and are planning this phase II trial, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top